Floatz logo

Saponin-Based Immunoadjuvant Obi-821

Primary Peritoneal Cavity Cancer

Gynecologic Oncology GroupmixturePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

154 Active assets in the Primary Peritoneal Cavity Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
GOG Foundation
Phase 3BBB
Carboplatin
University of Washington
Phase 3BBB
Inno-206
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
Hycamtin
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
PEGFILGRASTIM
TORL Biotherapeutics, LLC
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Saponin-Based Immunoadjuvant Obi-821 is also rated in:

breast cancerDormant
B
Indicative ·
58 / 100
View asset →
fallopian tube cancerDormant
B
Indicative ·
57 / 100
View asset →
primary peritoneal carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →